Izotropic (CSE:IZO; OTCQB:IZOZF; FSE:1R3) announced its inclusion in a Research and Markets (R&M) report analyzing the US breast cancer screening and diagnostic market.
According to Izotropic, the R&M analysis projects a robust and steady growth in the sector, with the market expanding from $1.55 billion in 2023 to $2.34 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.05%. This highlights Izotropic’s strategic timing in pursuing regulatory authorization and positioning its first medical imaging device, IzoView.
The company describes IzoView as a disruptive device offering ultra-high-resolution, true 3D, dedicated breast CT imaging. It is designed as a complementary screening tool to digital breast tomosynthesis (DBT), also known as 3D mammography, particularly for patients with dense breast tissue.
Furthermore, the R&M report states: “the US breast cancer screening and diagnostic, image-based market was led by the digital breast tomosynthesis segment, which held a 49.93% share in 2023 [and that the] rising adoption of digital breast tomosynthesis reflects a strong demand for advanced breast cancer screening technologies. DBT is particularly effective in improving detection rates for women with dense breast tissue, making it a vital tool for early diagnosis.”
